|Title: Pharmacokinetics of PEG-Interferon lambda (PEG-IFN-λ) Following Fixed Dosing in Treatment-Naïve Hepatitis C Subjects (Single Dose Interim Data from a Dose-Ranging Phase 2A Study) Abstract: 830 Presenter: K.A. Byrnes-Blake Date: Sunday, October 31, 2010 Time: 8:00 AM – 5:30 PM|
|Title: The Effect of Treatment Group, HCV Genotype, and IL28B Genotype on Early HCV Viral Kinetics in a Phase 2A Study of PEG-Interferon lambda (PEG-IFN-λ) in Hepatitis C Patients Abstract: 831 Presenter: J.A. Freeman Date: Sunday, October 31, 2010 Time: 8:00 AM – 5:30 PM|
|Title: In vitro activity of the combination of pegylated interferon lambda (PEG-IFN-λ) with direct-acting antivirals in the HCV replicon model Abstract: 1854 Presenter: F. McPhee Date: Tuesday, November 2, 2010 Time: 7:00 AM - 12:00 PM|
ZymoGenetics And Bristol-Myers Squibb To Present PEG-Interferon Lambda Phase 2a Interim Clinical Trial Results At AASLD 2010
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.